moneyheap
ZBH · Analysis updated Nov 4, 2026, 4:12 PM ET
Why is Zimmer Biomet Holdings, Inc. (ZBH) stock moving?
Zimmer Biomet's third-quarter sales rose 3.1% to $2.06 billion (3.7% in constant currency), slightly above estimates, and adjusted earnings of $1.90 a share were flat with a year ago and just ahead of forecasts. Hips grew 7%, sports medicine, extremities and trauma 7.1%, and its technology and surgical unit 13%, while knees, about 37% of sales, fell 2.6%. The company raised its 2026 organic constant-currency growth outlook to 3.0-3.5% (from 2.25-3.25%) and nudged adjusted earnings to $8.50-8.60 a share. The stock closed up about 13% at $110.12, after touching a 52-week high of $112.55.
News behind the analysis
- Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, 'Validating the Progress' of Its StrategyHips +7%, technology +13%; organic growth outlook raised to 3.0-3.5%.
- Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View UpSales $2.06B (+3.1%); adjusted EPS $1.90; 2026 view raised.
- Evercore ISI Adjusts Price Target on Zimmer Biomet to $122 From $115Target raised after the report.
- Hospital stocks rally while drugmakers brace for scrutiny. Here's what the Democratic wave means for healthcare.Healthcare providers and device makers rallied after the midterm results.
In the Daily Standout
- November 4, 2026: on the shortlist +13.45%